Patients belonging to the SGLT2 inhibitors and sulphonylureas monotherapy groups showed reduced and elevated GV with lowest and highest SD, MAGE, M100, GRADE, and % GRADE (hyperglycemia), respectively, in comparison to the other groups. This evidence concerns the gene SLC5A2 and Hyperglycemia.